Physician profile
Vera Stricevic
NPI 1104858968
$6,043.49
in general payments reported to CMS, 2019-2025
30 companies · $970 in 2025
The $970 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $165 · 2021: $1,199 · 2022: $1,052 · 2023: $1,228 · 2024: $573 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,746 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.28 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $722.37 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $631.43 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $565.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $458.08 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $400.84 | 2019-2023 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $308.35 | 2019-2024 | Rayaldee |
| Baxter Healthcare | $302.68 | 2019-2023 | Renal - Chronic, Renal - Pd |
| Horizon Therapeutics Plc | $264.69 | 2020-2023 | Krystexxa |
| Amgen INC. | $251.47 | 2019-2025 | Tavneos, Krystexxa |
| Akebia Therapeutics INC | $234.05 | 2021-2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $226.75 | 2019-2025 | Jynarque |
| Vantive US Healthcare LLC | $202.54 | 2025 | Renal - Pd |
| Aurinia Pharma U.S., INC. | $183.69 | 2021-2023 | Lupkynis |
| Glaxosmithkline, LLC. | $158.57 | 2020-2023 | Jesduvroq |
| Coala Life INC | $153.27 | 2023 | Coala Heart Monitor |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $151.36 | 2021-2025 | |
| Nxstage Medical, INC. | $131.75 | 2022 | |
| Calliditas Therapeutics US INC. | $127.91 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $117.27 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $111.02 | 2019 | |
| Alnylam Pharmaceuticals INC. | $80.89 | 2022-2023 | Onpattro |
| Ardelyx, INC. | $79.39 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $50.53 | 2019-2023 | Velphoro |
| Lilly USA, LLC | $35.50 | 2024 | Jardiance |
| Apellis Pharmaceuticals, INC. | $18.84 | 2025 | |
| Sanofi-Aventis U.S. LLC | $18.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.96 | 2021 | |
| Scpharmaceuticals INC. | $15.56 | 2025 | |
| Nestle Healthcare Nutrition INC. | $13.32 | 2022 | |
| Avion Pharmaceuticals | $11.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Stricevic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.